Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer - Wikidata - thesis-toulmin - TriplyDB

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

http://www.wikidata.org/entity/Q24653934

about

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Therapeutic targeting of cancers with loss of PTEN function.Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2 Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.Targeting PTEN-defined breast cancers with a one-two punch.PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype.High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression.Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells.A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancer.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer The changing role of ER in endocrine resistance.Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.PTEN mutation, methylation and expression in breast cancer patients.Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

P2860

Q26824462-86AE7A2F-4196-4415-89FA-B555B1EA1193 Q26862550-02508F93-4403-4E23-ADFA-4F704C54DA18 Q27852764-2A66238B-FF1D-424A-9367-9A38B8643E42 Q28085004-25B3AC05-C8DE-47E3-8716-F5C79F97A63E Q30419997-4011D319-EF76-470F-951B-D90F18A5A37D Q33843662-94D61FF4-DA5A-448F-86F3-C677EC235151 Q33862290-6BC25D9A-AC6F-47FE-BD49-CD65EC98FF9D Q33925164-ADC52944-125C-4490-AB0C-735DD3E2E707 Q33968076-FE187136-B118-40FB-A404-8515D0B6D01F Q34103963-0065369F-AFD6-4832-818B-7638639E80B2 Q34394399-A92EAEFA-6762-4BE0-8B84-75DBE10C1E11 Q34659897-3FFC5DC5-79E2-4C61-B6AB-B23F7E82DD5A Q34989077-4A61BB23-E43C-45CF-9418-1F4BED6304F0 Q34995919-9C43126B-FB70-4043-AC95-ACB462016E93 Q35000243-3148A62E-AA95-49D3-AB33-5E15F336112C Q35038068-4E1DFB3A-5318-4FA1-A807-AB66317015CB Q35127249-67945952-8A3D-43FE-9846-604AE3CBA777 Q35145443-35256638-CC1E-4247-AA87-EAAAFE9633ED Q35201923-D73FB55A-DF0A-42A5-BDB5-EBA778584716 Q35288044-67FCC1D5-542C-4D91-93D8-0D881D69AA0A Q35312683-BD36B4C1-99F2-4221-ABB9-9D730FE56BF3 Q35690099-01F0209C-75C6-4F3A-8BFD-F889D210267B Q35709435-52FB2825-D997-4265-BC4D-3765B3A319E7 Q35734750-A2E52D30-8D70-4A32-BCF5-B5DC7FCAF067 Q35810031-56C1AEC8-2B12-4CCB-A76B-45030F0CE3AF Q35861503-39BE962D-8747-4EEF-983C-CC420B035F9A Q36116250-D389F78B-2F5D-46DB-A829-8222DA6FB2E9 Q36188758-5D74F8BF-3C1A-4A12-BB11-1CFEC8578E65 Q36230591-5A86DFD1-870A-4651-A4BD-664E8F169431 Q36255950-1927221D-1519-400E-9504-982C5C2BCEDF Q36287691-5426F035-B461-48FB-A828-93F5CC2C08D2 Q36336601-8C3D57B8-7BB4-42C3-AEA7-CCF309F0EB90 Q36420373-F2DEE9B6-D9C3-4A52-ACA8-C38972C19588 Q36589865-4714CD48-A6B5-4BC0-928A-E4B94349842B Q36703783-832894E3-F990-48A7-B7AB-8766AC3C65B8 Q36854062-0466F5E7-462D-46CA-9835-B7DE1C042DB4 Q36863266-29DD5919-C25F-44BE-B8D2-24A0DBA5F283 Q36957145-823E1056-A024-468E-B77C-B2871C2D3104 Q37092758-DD4375B8-05E8-420A-AD74-DDFCEAEB5533 Q37168778-1FCBD126-E555-4C59-AF31-1AEACEC544FF

P2860

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

http://www.wikidata.org/entity/Q24653934

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@ast

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@en

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@nl

type

label

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@ast

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@en

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@nl

prefLabel

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@ast

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@en

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@nl

P1433

Q24653934-B213D7DC-BAD4-42B8-8ECB-2C5556242054

P1476

Q24653934-5C4A4223-EABF-4581-8D79-80524E15D26A

P2093

Q24653934-134954CE-D077-4299-865F-C86DE274A641

Q24653934-161C65A7-586B-411D-8ED3-55CBDEDAE28B

Q24653934-3EC7C9DC-F9C7-497A-BF07-039F32A901D6

Q24653934-487F6180-87ED-48A5-8E73-1FD16D9AC82F

Q24653934-4E6B12E2-0705-4F68-B34E-2DB61755BF5A

Q24653934-6CF503D5-E419-44E1-8883-9FCDD6D12874

Q24653934-72B451C1-97B0-4899-B359-F475AB2BB902

Q24653934-9D6F1BD7-AC1D-4D28-A4DE-99681C8F5AB1

Q24653934-A6AD9D38-432A-476F-B2F5-B12A829AE3D7

Q24653934-D7EE29A0-A7C5-4B1E-8FB6-8B8D6904E359

P2860

Q24653934-02B48D91-87F4-47C0-B3E1-6CA0D7A415D6

Q24653934-050EB519-4B6D-4A53-85FD-9A91EA061B63

Q24653934-08FD54D8-1149-44E6-BA6F-8D6E65F2AC32

Q24653934-0A93A5B5-3B3F-438F-9F5F-822138D22994

Q24653934-0EF69C9B-701A-4542-A4FF-93DB369717B6

Q24653934-17484905-B020-4481-AEC0-445E9ABFFBA0

Q24653934-1966E76A-79BD-4DBA-80BA-152D4E522F3A

Q24653934-238EF01B-02AB-4D50-9403-3ED7FE55DE22

Q24653934-2D03DD93-002C-4E1A-A608-309830E4C35D

Q24653934-2DA825BB-A69A-4661-8A49-3EEE6F9B90D8

P304

Q24653934-6AE034E1-5E04-498B-8EED-1D3EE2D870C0

P31

Q24653934-0598623B-95AF-4F27-B915-54C61B45FA8E

P356

Q24653934-B5DDC1FB-2F75-4301-890A-0DF99FFD277A

P407

Q24653934-EEB9D3F5-E7C9-4277-BE55-6E8D77093208

P433

Q24653934-700BBEA5-48D9-4A26-A91A-B26EF4E664E4

P478

Q24653934-29E4B337-8BD2-4B3F-9DCF-BB4254B1934F

P50

Q24653934-733AFC5A-7A8F-4893-9353-8041BAE85BE4

P577

Q24653934-10F6D674-B159-4D38-9067-AED3F19CA966

P698

Q24653934-C0411AF8-9A96-4CEA-A21F-AF3E841C4D31

P921

Q24653934-85D9706B-81B6-4191-9C73-8BE4C85CB2E1

P932

Q24653934-40E2D1CA-D878-4B79-8CB8-3909E134CF2A

P356

0008-5472.CAN-09-0042

P1433

Cancer Research

P1476

Loss of Phosphatase and Tensin ...... en resistance in breast cancer

@en

P2093

Ana M Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

Archana Narasanna

http://www.w3.org/2001/XMLSchema#string

Bryan T Hennessy

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Gizeh Pérez-Tenorio

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

J Phillip Kennedy

http://www.w3.org/2001/XMLSchema#string

Marianela Pérez-Torres

http://www.w3.org/2001/XMLSchema#string

Marta Guix

http://www.w3.org/2001/XMLSchema#string

Olle Stål

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN

P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase

PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

FAK integrates growth-factor and integrin signals to promote cell migration

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

P304

4192-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-0042

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Craig W. Lindsley

P577

2009-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19435893

http://www.w3.org/2001/XMLSchema#string

P921

P932

2724871

http://www.w3.org/2001/XMLSchema#string